Clinical trials
Bronchitis, Chronic trials in Canada
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
25 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 2 |
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2008 | 1 |
| 2009 | 4 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 3 |
| 2016 | 3 |
| 2017 | 2 |
| 2020 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 23 |
| Recruiting | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 7 |
| University of Alberta | 5 |
| McGill University Health Centre/Research Institute of the McGill University Health Centre | 2 |
| Bayer | 1 |
| CSA Medical, Inc. | 1 |
| Eli Lilly and Company | 1 |
| Gala Therapeutics, Inc. | 1 |
| London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 1 |
| Pfizer | 1 |
| Sanofi | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bronchitis, Chronic | 25 |
| Pulmonary Disease, Chronic Obstructive | 22 |
| Emphysema | 14 |
| Asthma | 3 |
| Lung Diseases | 3 |
| Alzheimer Disease | 2 |
| Anxiety Disorders | 2 |
| Arthritis | 2 |
| Arthritis, Rheumatoid | 2 |
| Cardiovascular Diseases | 2 |
Trials
Showing 51 to 25 of 25. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.